Abstract
Osimertinib is one of the standard first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, little is known about the clinical efficacy of osimertinib in NSCLC patients with malignant pleural effusion (MPE). Here, we evaluated the efficacy of osimertinib on these patients in the first line setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
